A Mab A Case Study In Bioprocess Development ⚡ [ TOP ]
The A-Mab case study remains a monumental achievement in bioprocess development, providing a clear, practical roadmap for applying science and risk-based quality by design. It taught the industry that proactively building quality into a process is not only achievable but also superior to relying on end-product testing.
Once the CQAs are identified, the next step is to develop a deep mechanistic understanding of how manufacturing process parameters affect these CQAs. This involves systematic experimentation, often using Design of Experiments (DoE) methodologies, to map the relationship between inputs (e.g., bioreactor pH, temperature, mixing speed) and outputs (e.g., cell growth, titer, glycosylation profile).
To overcome these limitations, a comprehensive optimization program was implemented, focusing on:
The team is now evaluating a continuous manufacturing (connected N-1 perfusion to capture) for Phase II to further reduce COGs by an estimated 35%. A Mab A Case Study In Bioprocess Development
A fed-batch strategy was implemented, feeding specific amino acids, glucose, and vitamins dynamically based on daily metabolite consumption rates. This averted nutrient starvation and limited the accumulation of toxic byproducts like lactate and ammonia. Bioreactor Scale-Up
This step achieved > 95% purity and a 98% recovery yield, removing the vast majority of host cell proteins (HCP) and DNA. Viral Inactivation (Low pH)
As mAb titers from upstream processes have increased (from ~1 g/L a decade ago to over 10 g/L today), the downstream process has often become the bottleneck. New technologies and strategies are emerging to address this. One innovative approach, described by Bio-Rad, involves using a two-step purification process that replaces the two traditional polishing columns with a single strong anion exchange-hydrophobic interaction chromatography (AEX-HIC) mixed-mode resin, reducing costs and increasing yield. Similarly, membrane chromatography is being validated as a high-productivity alternative to resin-packed columns for polishing, enabling faster processing. The A-Mab case study itself provides a hypothetical yet thorough risk assessment for each of these downstream unit operations, using leached Protein A, DNA, and other impurities as examples of attributes to be controlled. The A-Mab case study remains a monumental achievement
No bioprocess case study is complete without analytics. The Mab-X team implements a real-time process analytical technology (PAT) framework:
Before a single cell is cultured, the team defines the . For A Mab, an IgG1 targeting the PD-1 receptor for non-small cell lung cancer, the TPP specified:
A real-world challenge comes into sharp focus when a client approaches a CDMO with an initial process ill-suited for commercial manufacturing. A case study from Avid Bioservices illustrates this perfectly. A client had developed a mAb process that, at manufacturing scale, would require large chromatography columns, extended run times, and long hold steps—a recipe for high costs and low efficiency. Working under a compressed , the development team executed a "facility-fit" strategy. They performed early calculations to model column sizing and cycle times, screened high-capacity resins to reduce chromatography cycle count by over 50% , and used worst-case starting material to ensure robustness. The result? A process that lowered production costs by 25% and transferred smoothly with no unexpected issues. 4. Analytical Characterization and Quality Control
The traditional "batch" mindset—where processes are a series of discrete, start-stop steps—is giving way to a more integrated, continuous paradigm. This shift is perhaps the most significant trend in bioprocessing, promising smaller facility footprints, lower capital costs, and increased agility. The development story of A-mAb concludes with a look at this horizon, as exemplified by the .
A tangential flow filtration (TFF) system with a 30 kDa regenerated cellulose membrane concentrated the mAb to its final target formulation of 100 mg/mL. It simultaneously exchanged the buffer into a histidine-sucrose formulation stabilizing the drug substance for long-term storage. 4. Analytical Characterization and Quality Control
